Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Ching-Lin Hsieh, Jory A Goldsmith, Jeffrey M Schaub, Andrea M DiVenere, Hung-Che Kuo, Kamyab Javanmardi, Kevin C Le, Daniel Wrapp, Alison G Lee, Yutong Liu, Chia-Wei Chou, Patrick O Byrne, Christy K Hjorth, Nicole V Johnson, John Ludes-Meyers, Annalee W Nguyen, Juyeon Park, Nianshuang Wang, Dzifa Amengor, Jason J Lavinder, Gregory C Ippolito, Jennifer A Maynard, Ilya J Finkelstein, Jason S McLellan, Ching-Lin Hsieh, Jory A Goldsmith, Jeffrey M Schaub, Andrea M DiVenere, Hung-Che Kuo, Kamyab Javanmardi, Kevin C Le, Daniel Wrapp, Alison G Lee, Yutong Liu, Chia-Wei Chou, Patrick O Byrne, Christy K Hjorth, Nicole V Johnson, John Ludes-Meyers, Annalee W Nguyen, Juyeon Park, Nianshuang Wang, Dzifa Amengor, Jason J Lavinder, Gregory C Ippolito, Jennifer A Maynard, Ilya J Finkelstein, Jason S McLellan

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has led to accelerated efforts to develop therapeutics and vaccines. A key target of these efforts is the spike (S) protein, which is metastable and difficult to produce recombinantly. We characterized 100 structure-guided spike designs and identified 26 individual substitutions that increased protein yields and stability. Testing combinations of beneficial substitutions resulted in the identification of HexaPro, a variant with six beneficial proline substitutions exhibiting higher expression than its parental construct (by a factor of 10) as well as the ability to withstand heat stress, storage at room temperature, and three freeze-thaw cycles. A cryo-electron microscopy structure of HexaPro at a resolution of 3.2 angstroms confirmed that it retains the prefusion spike conformation. High-yield production of a stabilized prefusion spike protein will accelerate the development of vaccines and serological diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Figures

Fig. 1. Exemplary substitutions for SARS-CoV-2 spike…
Fig. 1. Exemplary substitutions for SARS-CoV-2 spike stabilization.
Side view of the trimeric SARS-CoV-2 spike ectodomain in a prefusion conformation (PDB ID: 6VSB). The S1 domains are shown as a transparent molecular surface. The S2 domain for each protomer is shown as a ribbon diagram. Each inset corresponds to one of four types of spike modifications (proline, salt bridge, disulfide, cavity filling). Side chains in each inset are shown as red spheres (proline), yellow sticks (disulfide), red and blue sticks (salt bridge) and orange spheres (cavity filling).
Fig. 2. Characterization of single-substitution spike variants.
Fig. 2. Characterization of single-substitution spike variants.
(A) SDS-PAGE of SARS-CoV-2 S-2P and single-substitution spike variants. Molecular weight standards are indicated at the left in kDa. (B to D) Size-exclusion chromatography traces of purified spike variants, grouped by type (B, disulfide variants; C, cavity filling and salt bridge; D, proline). A vertical dotted line indicates the characteristic peak retention volume for S-2P. (E) Representative negative stain electron micrographs for four variants. (F) Differential scanning fluorimetry analysis of spike variant thermostability. The vertical dotted line indicates the first apparent melting temperature for S-2P. (G) Expression levels of individual variants determined by quantitative biolayer interferometry. Variants are colored by type. The horizontal dotted line indicates the calculated concentration of S-2P, which was used as a control for comparison. The mean of three biological replicates is plotted, with error bars indicating standard deviations.
Fig. 3
Fig. 3
Characterization of multi-substitution spike variants. (A) SDS-PAGE of SARS-CoV-2 Combo variants. Molecular weight standards are indicated at the left in kDa. (B) SEC traces for S-2P, A892P and four Combo variants. The vertical dotted line indicates the peak retention volume for S-2P. (C) DSF analysis of Combo variant thermostability. The black vertical dotted line indicates the first apparent melting temperature for S-2P and the green vertical dotted line indicates the first apparent melting temperature for Combo47 (HexaPro). (D) Negative stain electron micrograph of purified Combo47 (HexaPro). (E) Binding of S-2P or HexaPro to convalescent human sera, mAb CR3022 and negative control serum (GNEG), measured by ELISA.
Fig. 4
Fig. 4
High-resolution cryo-EM structure of HexaPro. (A) EM density map of trimeric HexaPro. Each protomer is shown in a different color; the protomer depicted in wheat adopts the RBD-up conformation. (B) Alignment of an RBD-down protomer from HexaPro (green ribbon) with an RBD-down protomer from S-2P (white ribbon, PDB ID: 6VSB). (C) Zoomed view of the four proline substitutions unique to HexaPro. The EM density map is shown as a transparent surface and individual atoms are shown as sticks. Nitrogen atoms are colored blue and oxygen atoms are colored red.

References

    1. Chan J. F. W., Yuan S., Kok K. H., To K. K. W., Chu H., Yang J., Xing F., Liu J., Yip C. C. Y., Poon R. W. S., Tsoi H. W., Lo S. K. F., Chan K. H., Poon V. K. M., Chan W. M., Ip J. D., Cai J. P., Cheng V. C. C., Chen H., Hui C. K. M., Yuen K. Y., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 395, 514–523 (2020). 10.1016/S0140-6736(20)30154-9
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020). 10.1016/S0140-6736(20)30183-5
    1. Li F., Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu. Rev. Virol. 3, 237–261 (2016). 10.1146/annurev-virology-110615-042301
    1. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T. S., Herrler G., Wu N. H., Nitsche A., Müller M. A., Drosten C., Pöhlmann S., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271–280.e8 (2020). 10.1016/j.cell.2020.02.052
    1. Wan Y., Shang J., Graham R., Baric R. S., Li F., Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J. Virol. 94, e00127 (2020). 10.1128/JVI.00127-20
    1. Zhou P., Yang X. L., Wang X. G., Hu B., Zhang L., Zhang W., Si H. R., Zhu Y., Li B., Huang C. L., Chen H. D., Chen J., Luo Y., Guo H., Jiang R. D., Liu M. Q., Chen Y., Shen X. R., Wang X., Zheng X. S., Zhao K., Chen Q. J., Deng F., Liu L. L., Yan B., Zhan F. X., Wang Y. Y., Xiao G. F., Shi Z. L., A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). 10.1038/s41586-020-2012-7
    1. Bosch B. J., van der Zee R., de Haan C. A., Rottier J. M., The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. J. Virol. 77, 8801–8811 (2003). 10.1128/JVI.77.16.8801-8811.2003
    1. Walls A. C., Tortorici M. A., Snijder J., Xiong X., Bosch B. J., Rey F. A., Veesler D., Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc. Natl. Acad. Sci. U.S.A. 114, 11157–11162 (2017). 10.1073/pnas.1708727114
    1. Buchholz U. J., Bukreyev A., Yang L., Lamirande E. W., Murphy B. R., Subbarao K., Collins P. L., Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. U.S.A. 101, 9804–9809 (2004). 10.1073/pnas.0403492101
    1. Hofmann H., Hattermann K., Marzi A., Gramberg T., Geier M., Krumbiegel M., Kuate S., Überla K., Niedrig M., Pöhlmann S., S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J. Virol. 78, 6134–6142 (2004). 10.1128/JVI.78.12.6134-6142.2004
    1. Pallesen J., Wang N., Corbett K. S., Wrapp D., Kirchdoerfer R. N., Turner H. L., Cottrell C. A., Becker M. M., Wang L., Shi W., Kong W.-P., Andres E. L., Kettenbach A. N., Denison M. R., Chappell J. D., Graham B. S., Ward A. B., McLellan J. S., Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. U.S.A. 114, E7348–E7357 (2017). 10.1073/pnas.1707304114
    1. Sanders R. W., Derking R., Cupo A., Julien J.-P., Yasmeen A., de Val N., Kim H. J., Blattner C., de la Peña A. T., Korzun J., Golabek M., de Los Reyes K., Ketas T. J., van Gils M. J., King C. R., Wilson I. A., Ward A. B., Klasse P. J., Moore J. P., A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLOS Pathog. 9, e1003618 (2013). 10.1371/journal.ppat.1003618
    1. Crank M. C., Ruckwardt T. J., Chen M., Morabito K. M., Phung E., Costner P. J., Holman L. A., Hickman S. P., Berkowitz N. M., Gordon I. J., Yamshchikov G. V., Gaudinski M. R., Kumar A., Chang L. A., Moin S. M., Hill J. P., DiPiazza A. T., Schwartz R. M., Kueltzo L., Cooper J. W., Chen P., Stein J. A., Carlton K., Gall J. G., Nason M. C., Kwong P. D., Chen G. L., Mascola J. R., McLellan J. S., Ledgerwood J. E., Graham B. S., VRC 317 Study Team , A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365, 505–509 (2019). 10.1126/science.aav9033
    1. Park Y. J., Walls A. C., Wang Z., Sauer M. M., Li W., Tortorici M. A., Bosch B. J., DiMaio F., Veesler D., Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. Nat. Struct. Mol. Biol. 26, 1151–1157 (2019). 10.1038/s41594-019-0334-7
    1. Li Z., Tomlinson A. C. A., Wong A. H. M., Zhou D., Desforges M., Talbot P. J., Benlekbir S., Rubinstein J. L., Rini J. M., The human coronavirus HCoV-229E S-protein structure and receptor binding. eLife 8, e51230 (2019). 10.7554/eLife.51230
    1. Wang N., Rosen O., Wang L., Turner H. L., Stevens L. J., Corbett K. S., Bowman C. A., Pallesen J., Shi W., Zhang Y., Leung K., Kirchdoerfer R. N., Becker M. M., Denison M. R., Chappell J. D., Ward A. B., Graham B. S., McLellan J. S., Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. Cell Rep. 28, 3395–3405.e6 (2019). 10.1016/j.celrep.2019.08.052
    1. Walls A. C., Xiong X., Park Y.-J., Tortorici M. A., Snijder J., Quispe J., Cameroni E., Gopal R., Dai M., Lanzavecchia A., Zambon M., Rey F. A., Corti D., Veesler D., Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. Cell 176, 1026–1039.e15 (2019). 10.1016/j.cell.2018.12.028
    1. Wrapp D., Wang N., Corbett K. S., Goldsmith J. A., Hsieh C. L., Abiona O., Graham B. S., McLellan J. S., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020). 10.1126/science.abb2507
    1. Walls A. C., Park Y. J., Tortorici M. A., Wall A., McGuire A. T., Veesler D., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281–292.e6 (2020). 10.1016/j.cell.2020.02.058
    1. McLellan J. S., Chen M., Joyce M. G., Sastry M., Stewart-Jones G. B. E., Yang Y., Zhang B., Chen L., Srivatsan S., Zheng A., Zhou T., Graepel K. W., Kumar A., Moin S., Boyington J. C., Chuang G.-Y., Soto C., Baxa U., Bakker A. Q., Spits H., Beaumont T., Zheng Z., Xia N., Ko S.-Y., Todd J.-P., Rao S., Graham B. S., Kwong P. D., Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592–598 (2013). 10.1126/science.1243283
    1. Rutten L., Lai Y.-T., Blokland S., Truan D., Bisschop I. J. M., Strokappe N. M., Koornneef A., van Manen D., Chuang G.-Y., Farney S. K., Schuitemaker H., Kwong P. D., Langedijk J. P. M., A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. Cell Rep. 23, 584–595 (2018). 10.1016/j.celrep.2018.03.061
    1. Krarup A., Truan D., Furmanova-Hollenstein P., Bogaert L., Bouchier P., Bisschop I. J. M., Widjojoatmodjo M. N., Zahn R., Schuitemaker H., McLellan J. S., Langedijk J. P. M., A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015). 10.1038/ncomms9143
    1. Rutten L., Gilman M. S. A., Blokland S., Juraszek J., McLellan J. S., Langedijk J. P. M., Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers. Cell Rep. 30, 4540–4550.e3 (2020). 10.1016/j.celrep.2020.03.025
    1. Battles M. B., Más V., Olmedillas E., Cano O., Vázquez M., Rodríguez L., Melero J. A., McLellan J. S., Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nat. Commun. 8, 1528 (2017). 10.1038/s41467-017-01708-9
    1. Qiao H., Pelletier S. L., Hoffman L., Hacker J., Armstrong R. T., White J. M., Specific single or double proline substitutions in the “spring-loaded” coiled-coil region of the influenza hemagglutinin impair or abolish membrane fusion activity. J. Cell Biol. 141, 1335–1347 (1998). 10.1083/jcb.141.6.1335
    1. Hastie K. M., Zandonatti M. A., Kleinfelter L. M., Heinrich M. L., Rowland M. M., Chandran K., Branco L. M., Robinson J. E., Garry R. F., Saphire E. O., Structural basis for antibody-mediated neutralization of Lassa virus. Science 356, 923–928 (2017). 10.1126/science.aam7260
    1. Yuan M., Wu N. C., Zhu X., Lee C. D., So R. T. Y., Lv H., Mok C. K. P., Wilson I. A., A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633 (2020). 10.1126/science.abb7269
    1. Tegunov D., Cramer P., Real-time cryo-electron microscopy data preprocessing with Warp. Nat. Methods 16, 1146–1152 (2019). 10.1038/s41592-019-0580-y
    1. Punjani A., Rubinstein J. L., Fleet D. J., Brubaker M. A., cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017). 10.1038/nmeth.4169
    1. Ramírez-Aportela E., Vilas J. L., Glukhova A., Melero R., Conesa P., Martínez M., Maluenda D., Mota J., Jiménez A., Vargas J., Marabini R., Sexton P. M., Carazo J. M., Sorzano C. O. S., Automatic local resolution-based sharpening of cryo-EM maps. Bioinformatics 36, 765–772 (2020).
    1. Emsley P., Lohkamp B., Scott W. G., Cowtan K., Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010). 10.1107/S0907444910007493
    1. Liebschner D., Afonine P. V., Baker M. L., Bunkóczi G., Chen V. B., Croll T. I., Hintze B., Hung L. W., Jain S., McCoy A. J., Moriarty N. W., Oeffner R. D., Poon B. K., Prisant M. G., Read R. J., Richardson J. S., Richardson D. C., Sammito M. D., Sobolev O. V., Stockwell D. H., Terwilliger T. C., Urzhumtsev A. G., Videau L. L., Williams C. J., Adams P. D., Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix. Acta Crystallogr. D 75, 861–877 (2019). 10.1107/S2059798319011471
    1. Croll T. I., ISOLDE: A physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D 74, 519–530 (2018). 10.1107/S2059798318002425

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe